Page last updated: 2024-12-08

bms 214662

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

7-cyano-2,3,4,5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3-(phenylmethyl)-4-(2-thienylsulfonyl)-1H-1,4-benzodiazepine: a farnesyltransferase inhibitor; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

BMS-214662 : A member of the class of benzodiazepines that is 2,3,4,5-tetrahydro-1H-1,4-benzodiazepine substituted by (1H-imidazol-5-yl)methyl, benzyl, (thiophen-2-yl)sulfonyl, and cyano groups at positions 1, 3R, 4 and 7, respectively. It is a potent inhibitor of farnesyltransferase (IC50 = 1.35nM) which was under clinical development for the treatment of solid tumors. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID448545
CHEMBL ID351706
CHEBI ID167655
SCHEMBL ID94663
MeSH IDM0460179

Synonyms (38)

Synonym
(r)-2,3,4,5-tetrahydro-1-(1h-imidazol-4-ylmethyl)-3-(phenylmethyl)-4-(2-thienylsulfonyl)-1h-1,4-benzodiazepine-7-carbonitrile
195987-41-8
(3r)-3-benzyl-1-(1h-imidazol-5-ylmethyl)-4-(thiophen-2-ylsulfonyl)-2,3,4,5-tetrahydro-1h-1,4-benzodiazepine-7-carbonitrile
CHEBI:167655
(3r)-3-benzyl-1-(1h-imidazol-5-ylmethyl)-4-thiophen-2-ylsulfonyl-3,5-dihydro-2h-1,4-benzodiazepine-7-carbonitrile
(r)-7-cyano-2,3,4,5-tetrahydro-1-(1h-imidazol-4-ylmethyl)-3-(phenylmethyl)-4-(2-thienylsulfonyl)-1h-1,4-benzodiazepine
bms214662
3-benzyl-1-(1h-imidazol-4-ylmethyl)-4-(thien-2-ylsulfonyl)-2,3,4,5-tetrahydro-1h-1,4-benzodiazepine-7-carbonitrile
BMV ,
bms-214662
bms 214662
(r)-1-((1h-imidazol-5-yl)methyl)-3-benzyl-4-(thiophen-2-ylsulfonyl)-2,3,4,5-tetrahydro-1h-benzo[e][1,4]diazepine-7-carbonitrile
(r)-3-benzyl-1-(3h-imidazol-4-ylmethyl)-4-(thiophene-2-sulfonyl)-2,3,4,5-tetrahydro-1h-benzo[e][1,4]diazepine-7-carbonitrile
bdbm50092365
(r)-3-benzyl-1-(1h-imidazol-4-ylmethyl)-4-(thiophene-2-sulfonyl)-2,3,4,5-tetrahydro-1h-benzo[e][1,4]diazepine-7-carbonitrile
3-benzyl-1-(3h-imidazol-4-ylmethyl)-4-(thiophene-2-sulfonyl)-2,3,4,5-tetrahydro-1h-benzo[e][1,4]diazepine-7-carbonitrile
CHEMBL351706 ,
unii-l2u9gfd244
7-cyano-2,3,4,5-tetrahydro-1-(1h-imidazol-4-ylmethyl)-3-(phenylmethyl)-4-(2-thienylsulfonyl)-1h-1,4-benzodiazepine
l2u9gfd244 ,
1h-1,4-benzodiazepine-7-carbonitrile, 2,3,4,5-tetrahydro-1-(1h-imidazol-4-ylmethyl)-3-(phenylmethyl)-4-(2-thienylsulfonyl)-, (3r)-
bms 214662 [who-dd]
1h-1,4-benzodiazepine-7-carbonitrile, 2,3,4,5-tetrahydro-1-(1h-imidazol-4-ylmethyl)-3-(phenylmethyl)-4-(2-thienylsulfonyl)-, (r)-
gtpl8026
(3r)-1-(3h-imidazol-4-ylmethyl)-3-(phenylmethyl)-4-thiophen-2-ylsulfonyl-3,5-dihydro-2h-1,4-benzodiazepine-7-carbonitrile
SCHEMBL94663
(r)-2,3,4,5-tetrahydro-1-(1h-imidazol-4-ylmethyl)-3-(phenylmethyl)-4-(2-thienyisulfonyl)-1h-1,4-benzodiazepine-7-carbonitile
OLCWFLWEHWLBTO-HSZRJFAPSA-N ,
DTXSID20173260
HY-16111
CS-6471
DB12234
(3r)-3-benzyl-1-(1h-imidazol-4-ylmethyl)-4-(thiophen-2-ylsulfonyl)-2,3,4,5-tetrahydro-1h-1,4-benzodiazepine-7-carbonitrile
BCP24307
Q27075336
MS-29107
VHA98741
AKOS040732621

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" The aims of this study were to characterize the toxicities and to determine the pharmacokinetic profiles of BMS-214662 when administered in combination with cisplatin, and to determine the constitutive farnesyltransferase activity as a surrogate pharmacodynamic end point."( A phase I pharmacokinetic and pharmacodynamic study of the farnesyl transferase inhibitor BMS-214662 in combination with cisplatin in patients with advanced solid tumors.
Crawford, D; Eskens, FA; Evans, TR; Hoekstra, R; Loos, WJ; Mackay, HJ; Van Vreckem, A; Verweij, J; Voi, M, 2004
)
0.32
" Blood and urine samples for pharmacokinetic and pharmacodynamic analyses were collected during the first cycle of treatment only."( A phase I pharmacokinetic and pharmacodynamic study of the farnesyl transferase inhibitor BMS-214662 in combination with cisplatin in patients with advanced solid tumors.
Crawford, D; Eskens, FA; Evans, TR; Hoekstra, R; Loos, WJ; Mackay, HJ; Van Vreckem, A; Verweij, J; Voi, M, 2004
)
0.32
" There was no apparent pharmacokinetic interaction between the two drugs at the recommended dose levels, and a dose-dependent inhibition of farnesyltransferase activity was observed, which returned to control levels within 24 h of drug administration."( A phase I pharmacokinetic and pharmacodynamic study of the farnesyl transferase inhibitor BMS-214662 in combination with cisplatin in patients with advanced solid tumors.
Crawford, D; Eskens, FA; Evans, TR; Hoekstra, R; Loos, WJ; Mackay, HJ; Van Vreckem, A; Verweij, J; Voi, M, 2004
)
0.32
" We have conducted a phase I pharmacokinetic (PK) and pharmacodynamic study of BMS-214662 administered intravenously weekly with 1- and 24-hour infusions."( Phase I pharmacokinetic and pharmacodynamic study of weekly 1-hour and 24-hour infusion BMS-214662, a farnesyltransferase inhibitor, in patients with advanced solid tumors.
Albanell, J; Andreu, J; Baselga, J; Bellmunt, J; Carulla, J; Cooper, M; Del Campo, JM; Felip, E; García, M; Garrido, C; Guix, M; Manne, V; Manning, JA; Marimón, I; Rojo, F; Tabernero, J; Valverde, S; Van Vreckem, A; Vázquez, F; Voi, M, 2005
)
0.33
"BMS-214662 can be safely delivered in both the 1-hour and 24-hour infusions at biologically active doses, with the preclinical, PK, and pharmacodynamic profiles favoring the 24-hour schedule."( Phase I pharmacokinetic and pharmacodynamic study of weekly 1-hour and 24-hour infusion BMS-214662, a farnesyltransferase inhibitor, in patients with advanced solid tumors.
Albanell, J; Andreu, J; Baselga, J; Bellmunt, J; Carulla, J; Cooper, M; Del Campo, JM; Felip, E; García, M; Garrido, C; Guix, M; Manne, V; Manning, JA; Marimón, I; Rojo, F; Tabernero, J; Valverde, S; Van Vreckem, A; Vázquez, F; Voi, M, 2005
)
0.33
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35

Compound-Compound Interactions

ExcerptReferenceRelevance
" The aims of this study were to characterize the toxicities and to determine the pharmacokinetic profiles of BMS-214662 when administered in combination with cisplatin, and to determine the constitutive farnesyltransferase activity as a surrogate pharmacodynamic end point."( A phase I pharmacokinetic and pharmacodynamic study of the farnesyl transferase inhibitor BMS-214662 in combination with cisplatin in patients with advanced solid tumors.
Crawford, D; Eskens, FA; Evans, TR; Hoekstra, R; Loos, WJ; Mackay, HJ; Van Vreckem, A; Verweij, J; Voi, M, 2004
)
0.32
"This phase I study was conducted to determine the toxicities, pharmacokinetics, and pharmacodynamics of BMS-214662, a farnesyl transferase inhibitor, in combination with paclitaxel and carboplatin, in patients with advanced solid tumors."( A phase I trial of the novel farnesyl protein transferase inhibitor, BMS-214662, in combination with paclitaxel and carboplatin in patients with advanced cancer.
Adjei, AA; Bruzek, LM; Cheng, S; Croghan, GA; Dy, GK; Erlichman, C; Furth, A; Hanson, LJ; Kaufmann, SH; Mandrekar, S; Martell, RE; Peethambaram, P; Pitot, HC; Reid, JM, 2005
)
0.33
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
apoptosis inducerAny substance that induces the process of apoptosis (programmed cell death) in multi-celled organisms.
EC 2.5.1.58 (protein farnesyltransferase) inhibitorAn EC 2.5.1.* (non-methyl-alkyl or aryl transferase) inhibitor that interferes with the action of protein farnesyltransferase (EC 2.5.1.58), one of the three enzymes in the prenyltransferase group.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (6)

ClassDescription
imidazolesA five-membered organic heterocycle containing two nitrogen atoms at positions 1 and 3, or any of its derivatives; compounds containing an imidazole skeleton.
nitrileA compound having the structure RC#N; thus a C-substituted derivative of hydrocyanic acid, HC#N. In systematic nomenclature, the suffix nitrile denotes the triply bound #N atom, not the carbon atom attached to it.
thiophenesCompounds containing at least one thiophene ring.
sulfonamideAn amide of a sulfonic acid RS(=O)2NR'2.
benzenesAny benzenoid aromatic compound consisting of the benzene skeleton and its substituted derivatives.
benzodiazepineA group of heterocyclic compounds with a core structure containing a benzene ring fused to a diazepine ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (7)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
PPM1D proteinHomo sapiens (human)Potency1.17090.00529.466132.9993AID1347411
Interferon betaHomo sapiens (human)Potency1.17090.00339.158239.8107AID1347411
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
GTPase HRasHomo sapiens (human)IC50 (µMol)0.00130.00130.06820.2000AID1893917; AID1895856
GTPase KRasHomo sapiens (human)IC50 (µMol)0.77230.00841.13345.8800AID1893915; AID1893916; AID1895857
Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)IC50 (µMol)0.36170.00050.471610.0000AID1371354; AID693812; AID71309; AID71325; AID73279; AID73400; AID754493; AID754494; AID89419; AID93988
Protein farnesyltransferase subunit betaHomo sapiens (human)IC50 (µMol)0.00210.00050.21772.5000AID1371354; AID693812; AID71309; AID71325; AID73279; AID73400; AID754493; AID754494
Geranylgeranyl transferase type-1 subunit betaHomo sapiens (human)IC50 (µMol)1.80000.00732.364210.0000AID89419; AID93988
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
GTPase HRasHomo sapiens (human)IC90 (µMol)0.01800.01800.01800.0180AID1893917
GTPase KRasHomo sapiens (human)IC90 (µMol)0.10800.10800.10800.1080AID1893916
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (99)

Processvia Protein(s)Taxonomy
regulation of cell cycleGTPase HRasHomo sapiens (human)
MAPK cascadeGTPase HRasHomo sapiens (human)
positive regulation of protein phosphorylationGTPase HRasHomo sapiens (human)
regulation of transcription by RNA polymerase IIGTPase HRasHomo sapiens (human)
endocytosisGTPase HRasHomo sapiens (human)
chemotaxisGTPase HRasHomo sapiens (human)
signal transductionGTPase HRasHomo sapiens (human)
cell surface receptor signaling pathwayGTPase HRasHomo sapiens (human)
Ras protein signal transductionGTPase HRasHomo sapiens (human)
positive regulation of cell population proliferationGTPase HRasHomo sapiens (human)
negative regulation of cell population proliferationGTPase HRasHomo sapiens (human)
insulin receptor signaling pathwayGTPase HRasHomo sapiens (human)
animal organ morphogenesisGTPase HRasHomo sapiens (human)
negative regulation of gene expressionGTPase HRasHomo sapiens (human)
positive regulation of phospholipase C activityGTPase HRasHomo sapiens (human)
Schwann cell developmentGTPase HRasHomo sapiens (human)
positive regulation of cell migrationGTPase HRasHomo sapiens (human)
positive regulation of type II interferon productionGTPase HRasHomo sapiens (human)
regulation of actin cytoskeleton organizationGTPase HRasHomo sapiens (human)
negative regulation of GTPase activityGTPase HRasHomo sapiens (human)
T-helper 1 type immune responseGTPase HRasHomo sapiens (human)
regulation of cell population proliferationGTPase HRasHomo sapiens (human)
myelinationGTPase HRasHomo sapiens (human)
defense response to protozoanGTPase HRasHomo sapiens (human)
positive regulation of MAP kinase activityGTPase HRasHomo sapiens (human)
positive regulation of MAPK cascadeGTPase HRasHomo sapiens (human)
negative regulation of neuron apoptotic processGTPase HRasHomo sapiens (human)
positive regulation of GTPase activityGTPase HRasHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIGTPase HRasHomo sapiens (human)
positive regulation of JNK cascadeGTPase HRasHomo sapiens (human)
fibroblast proliferationGTPase HRasHomo sapiens (human)
positive regulation of fibroblast proliferationGTPase HRasHomo sapiens (human)
regulation of long-term neuronal synaptic plasticityGTPase HRasHomo sapiens (human)
positive regulation of epithelial cell proliferationGTPase HRasHomo sapiens (human)
T cell receptor signaling pathwayGTPase HRasHomo sapiens (human)
neuron apoptotic processGTPase HRasHomo sapiens (human)
adipose tissue developmentGTPase HRasHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeGTPase HRasHomo sapiens (human)
cellular response to gamma radiationGTPase HRasHomo sapiens (human)
positive regulation of wound healingGTPase HRasHomo sapiens (human)
positive regulation of protein targeting to membraneGTPase HRasHomo sapiens (human)
cellular senescenceGTPase HRasHomo sapiens (human)
oncogene-induced cell senescenceGTPase HRasHomo sapiens (human)
intrinsic apoptotic signaling pathwayGTPase HRasHomo sapiens (human)
regulation of neurotransmitter receptor localization to postsynaptic specialization membraneGTPase HRasHomo sapiens (human)
positive regulation of ruffle assemblyGTPase HRasHomo sapiens (human)
positive regulation of miRNA metabolic processGTPase HRasHomo sapiens (human)
MAPK cascadeGTPase KRasHomo sapiens (human)
positive regulation of protein phosphorylationGTPase KRasHomo sapiens (human)
visual learningGTPase KRasHomo sapiens (human)
gene expressionGTPase KRasHomo sapiens (human)
positive regulation of gene expressionGTPase KRasHomo sapiens (human)
glial cell proliferationGTPase KRasHomo sapiens (human)
Rac protein signal transductionGTPase KRasHomo sapiens (human)
forebrain astrocyte developmentGTPase KRasHomo sapiens (human)
actin cytoskeleton organizationGTPase KRasHomo sapiens (human)
negative regulation of epithelial cell differentiationGTPase KRasHomo sapiens (human)
regulation of synaptic transmission, GABAergicGTPase KRasHomo sapiens (human)
positive regulation of Rac protein signal transductionGTPase KRasHomo sapiens (human)
skeletal muscle cell differentiationGTPase KRasHomo sapiens (human)
negative regulation of neuron apoptotic processGTPase KRasHomo sapiens (human)
regulation of long-term neuronal synaptic plasticityGTPase KRasHomo sapiens (human)
homeostasis of number of cells within a tissueGTPase KRasHomo sapiens (human)
striated muscle cell differentiationGTPase KRasHomo sapiens (human)
neuron apoptotic processGTPase KRasHomo sapiens (human)
positive regulation of glial cell proliferationGTPase KRasHomo sapiens (human)
epithelial tube branching involved in lung morphogenesisGTPase KRasHomo sapiens (human)
type I pneumocyte differentiationGTPase KRasHomo sapiens (human)
Ras protein signal transductionGTPase KRasHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
transforming growth factor beta receptor signaling pathwayProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
protein farnesylationProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
protein geranylgeranylationProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
positive regulation of Rac protein signal transductionProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
skeletal muscle acetylcholine-gated channel clusteringProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
positive regulation of tubulin deacetylationProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
positive regulation of deacetylase activityProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
positive regulation of skeletal muscle acetylcholine-gated channel clusteringProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
lipid metabolic processProtein farnesyltransferase subunit betaHomo sapiens (human)
protein farnesylationProtein farnesyltransferase subunit betaHomo sapiens (human)
protein geranylgeranylationGeranylgeranyl transferase type-1 subunit betaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (20)

Processvia Protein(s)Taxonomy
GTPase activityGTPase HRasHomo sapiens (human)
G protein activityGTPase HRasHomo sapiens (human)
protein bindingGTPase HRasHomo sapiens (human)
GTP bindingGTPase HRasHomo sapiens (human)
GDP bindingGTPase HRasHomo sapiens (human)
protein-membrane adaptor activityGTPase HRasHomo sapiens (human)
GTPase activityGTPase KRasHomo sapiens (human)
G protein activityGTPase KRasHomo sapiens (human)
protein bindingGTPase KRasHomo sapiens (human)
protein-membrane adaptor activityGTPase KRasHomo sapiens (human)
protein-containing complex bindingGTPase KRasHomo sapiens (human)
GDP bindingGTPase KRasHomo sapiens (human)
GTP bindingGTPase KRasHomo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
protein farnesyltransferase activityProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
protein farnesyltransferase activityProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
protein geranylgeranyltransferase activityProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
Rab geranylgeranyltransferase activityProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
protein bindingProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
microtubule bindingProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
receptor tyrosine kinase bindingProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
alpha-tubulin bindingProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
molecular adaptor activityProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
CAAX-protein geranylgeranyltransferase activityProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
protein farnesyltransferase activityProtein farnesyltransferase subunit betaHomo sapiens (human)
protein farnesyltransferase activityProtein farnesyltransferase subunit betaHomo sapiens (human)
protein bindingProtein farnesyltransferase subunit betaHomo sapiens (human)
zinc ion bindingProtein farnesyltransferase subunit betaHomo sapiens (human)
protein geranylgeranyltransferase activityGeranylgeranyl transferase type-1 subunit betaHomo sapiens (human)
CAAX-protein geranylgeranyltransferase activityGeranylgeranyl transferase type-1 subunit betaHomo sapiens (human)
protein bindingGeranylgeranyl transferase type-1 subunit betaHomo sapiens (human)
zinc ion bindingGeranylgeranyl transferase type-1 subunit betaHomo sapiens (human)
CAAX-protein geranylgeranyltransferase activityGeranylgeranyl transferase type-1 subunit betaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (19)

Processvia Protein(s)Taxonomy
glutamatergic synapseGTPase HRasHomo sapiens (human)
Golgi membraneGTPase HRasHomo sapiens (human)
nucleoplasmGTPase HRasHomo sapiens (human)
cytoplasmGTPase HRasHomo sapiens (human)
endoplasmic reticulum membraneGTPase HRasHomo sapiens (human)
Golgi apparatusGTPase HRasHomo sapiens (human)
cytosolGTPase HRasHomo sapiens (human)
plasma membraneGTPase HRasHomo sapiens (human)
perinuclear region of cytoplasmGTPase HRasHomo sapiens (human)
GTPase complexGTPase HRasHomo sapiens (human)
plasma membraneGTPase HRasHomo sapiens (human)
Golgi membraneGTPase KRasHomo sapiens (human)
cytoplasmGTPase KRasHomo sapiens (human)
mitochondrial outer membraneGTPase KRasHomo sapiens (human)
endoplasmic reticulum membraneGTPase KRasHomo sapiens (human)
cytosolGTPase KRasHomo sapiens (human)
plasma membraneGTPase KRasHomo sapiens (human)
focal adhesionGTPase KRasHomo sapiens (human)
cytoplasmic side of plasma membraneGTPase KRasHomo sapiens (human)
membraneGTPase KRasHomo sapiens (human)
plasma membraneGTPase KRasHomo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
cytosolProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
plasma membraneProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
CAAX-protein geranylgeranyltransferase complexProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
microtubule associated complexProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
protein farnesyltransferase complexProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
cytoplasmProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
cytosolProtein farnesyltransferase subunit betaHomo sapiens (human)
microtubule associated complexProtein farnesyltransferase subunit betaHomo sapiens (human)
protein farnesyltransferase complexProtein farnesyltransferase subunit betaHomo sapiens (human)
CAAX-protein geranylgeranyltransferase complexGeranylgeranyl transferase type-1 subunit betaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (44)

Assay IDTitleYearJournalArticle
AID754492Antitumor activity against human HCT116 cells xenograft model assessed as tumor cell kill at 75 mg/kg, iv after 24 hrs relative to control2013Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13
Targeting mutant KRAS for anticancer therapeutics: a review of novel small molecule modulators.
AID87563In vivo antitumor activity (no. of cures / total) by subcutaneous implantation of HCT116 tumors followed by oral administration at an optimal dose of 600 mg/kg in rat2000Journal of medicinal chemistry, Oct-05, Volume: 43, Issue:20
Discovery of (R)-7-cyano-2,3,4, 5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3- (phenylmethyl)-4-(2-thienylsulfonyl)-1H-1,4-benzodiazepine (BMS-214662), a farnesyltransferase inhibitor with potent preclinical antitumor activity.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID29644Oral bioavailability observed in rats at an oral dose of 50 mg/kg2000Journal of medicinal chemistry, Oct-05, Volume: 43, Issue:20
Discovery of (R)-7-cyano-2,3,4, 5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3- (phenylmethyl)-4-(2-thienylsulfonyl)-1H-1,4-benzodiazepine (BMS-214662), a farnesyltransferase inhibitor with potent preclinical antitumor activity.
AID526662Inhibition of FTase in mouse NIH3T3 cells2010Journal of medicinal chemistry, Oct-14, Volume: 53, Issue:19
Toward the development of innovative bifunctional agents to induce differentiation and to promote apoptosis in leukemia: clinical candidates and perspectives.
AID1893917Inhibition of HRAS (unknown origin) farnesylation2021European journal of medicinal chemistry, Feb-05, Volume: 211Targeting KRAS mutant cancers by preventing signaling transduction in the MAPK pathway.
AID503917Selectivity for protein farnesyltransferase over GGTase12006Nature chemical biology, Oct, Volume: 2, Issue:10
Therapeutic intervention based on protein prenylation and associated modifications.
AID1893913Inhibition of human recombinant FTase2021European journal of medicinal chemistry, Feb-05, Volume: 211Targeting KRAS mutant cancers by preventing signaling transduction in the MAPK pathway.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID30137Volume of distribution (Vss) in rats following intravenous dose of 50 mg/kg2000Journal of medicinal chemistry, Oct-05, Volume: 43, Issue:20
Discovery of (R)-7-cyano-2,3,4, 5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3- (phenylmethyl)-4-(2-thienylsulfonyl)-1H-1,4-benzodiazepine (BMS-214662), a farnesyltransferase inhibitor with potent preclinical antitumor activity.
AID109853Percent control tumor size in mouse xenograft assay (rat H-ras transformed fibroblasts) at 200 mg/kg peroral dose2004Bioorganic & medicinal chemistry letters, Feb-09, Volume: 14, Issue:3
Synthesis of N,N'-disubstituted 3-aminobenzo[c] and [d]azepin-2-ones as potent and specific farnesyl transferase inhibitors.
AID73400Inhibitory concentration against farnesyltransferase was determined2004Journal of medicinal chemistry, Apr-08, Volume: 47, Issue:8
Inhibitors of farnesyltransferase: a rational approach to cancer chemotherapy?
AID27659Half-life of compound in rats following intravenous dose of 50 mg/kg2000Journal of medicinal chemistry, Oct-05, Volume: 43, Issue:20
Discovery of (R)-7-cyano-2,3,4, 5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3- (phenylmethyl)-4-(2-thienylsulfonyl)-1H-1,4-benzodiazepine (BMS-214662), a farnesyltransferase inhibitor with potent preclinical antitumor activity.
AID197124Percent phenotypic reversion of H-ras transformed Rat-1 cells at 0.1 uM2000Journal of medicinal chemistry, Oct-05, Volume: 43, Issue:20
Discovery of (R)-7-cyano-2,3,4, 5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3- (phenylmethyl)-4-(2-thienylsulfonyl)-1H-1,4-benzodiazepine (BMS-214662), a farnesyltransferase inhibitor with potent preclinical antitumor activity.
AID1893914Inhibition of RAS-CVLL (unknown origin) geranylgeranylation2021European journal of medicinal chemistry, Feb-05, Volume: 211Targeting KRAS mutant cancers by preventing signaling transduction in the MAPK pathway.
AID71325Inhibition of farnesyltransferase2004Bioorganic & medicinal chemistry letters, Feb-09, Volume: 14, Issue:3
Synthesis of N,N'-disubstituted 3-aminobenzo[c] and [d]azepin-2-ones as potent and specific farnesyl transferase inhibitors.
AID1893916Inhibition of K-Ras (unknown origin) farnesylation2021European journal of medicinal chemistry, Feb-05, Volume: 211Targeting KRAS mutant cancers by preventing signaling transduction in the MAPK pathway.
AID1371355Inhibition of human recombinant GGTase2018Journal of medicinal chemistry, 04-26, Volume: 61, Issue:8
Interrogating the Roles of Post-Translational Modifications of Non-Histone Proteins.
AID693812Inhibition of human FTase2012Bioorganic & medicinal chemistry letters, Nov-15, Volume: 22, Issue:22
Synthesis and biological evaluation of new phenothiazine derivatives bearing a pyrazole unit as protein farnesyltransferase inhibitors.
AID23904Clearance in rats following intravenous dose of 50 mg/kg2000Journal of medicinal chemistry, Oct-05, Volume: 43, Issue:20
Discovery of (R)-7-cyano-2,3,4, 5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3- (phenylmethyl)-4-(2-thienylsulfonyl)-1H-1,4-benzodiazepine (BMS-214662), a farnesyltransferase inhibitor with potent preclinical antitumor activity.
AID1371354Inhibition of human recombinant FTase2018Journal of medicinal chemistry, 04-26, Volume: 61, Issue:8
Interrogating the Roles of Post-Translational Modifications of Non-Histone Proteins.
AID89419Inhibition of geranylgeranyl transferase (GGT1) using Ras-CVLL as substrate2000Journal of medicinal chemistry, Oct-05, Volume: 43, Issue:20
Discovery of (R)-7-cyano-2,3,4, 5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3- (phenylmethyl)-4-(2-thienylsulfonyl)-1H-1,4-benzodiazepine (BMS-214662), a farnesyltransferase inhibitor with potent preclinical antitumor activity.
AID1893918Inhibition of FPTase (unknown origin)2021European journal of medicinal chemistry, Feb-05, Volume: 211Targeting KRAS mutant cancers by preventing signaling transduction in the MAPK pathway.
AID93988Inhibition of geranylgeranyl transferase (GGT1) using K-Ras as substrate2000Journal of medicinal chemistry, Oct-05, Volume: 43, Issue:20
Discovery of (R)-7-cyano-2,3,4, 5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3- (phenylmethyl)-4-(2-thienylsulfonyl)-1H-1,4-benzodiazepine (BMS-214662), a farnesyltransferase inhibitor with potent preclinical antitumor activity.
AID168709Inhibitory activity against v-H-Ras gene transfected cell line2004Bioorganic & medicinal chemistry letters, Feb-09, Volume: 14, Issue:3
Synthesis of N,N'-disubstituted 3-aminobenzo[c] and [d]azepin-2-ones as potent and specific farnesyl transferase inhibitors.
AID1895857Inhibition of human K-ras2021European journal of medicinal chemistry, Dec-15, Volume: 226Zinc enzymes in medicinal chemistry.
AID73279Inhibition of purified recombinant human farnesyltransferase (FT)2000Journal of medicinal chemistry, Oct-05, Volume: 43, Issue:20
Discovery of (R)-7-cyano-2,3,4, 5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3- (phenylmethyl)-4-(2-thienylsulfonyl)-1H-1,4-benzodiazepine (BMS-214662), a farnesyltransferase inhibitor with potent preclinical antitumor activity.
AID526660Inhibition of FTase2010Journal of medicinal chemistry, Oct-14, Volume: 53, Issue:19
Toward the development of innovative bifunctional agents to induce differentiation and to promote apoptosis in leukemia: clinical candidates and perspectives.
AID1895856Inhibition of human H-ras2021European journal of medicinal chemistry, Dec-15, Volume: 226Zinc enzymes in medicinal chemistry.
AID754494Inhibition of farnesyltransferase (unknown origin) assessed as HRAS farnesylation2013Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13
Targeting mutant KRAS for anticancer therapeutics: a review of novel small molecule modulators.
AID144124Inhibition of anchorage independent growth of H-ras transformed NIH3T3 cells in Soft Agar2000Journal of medicinal chemistry, Oct-05, Volume: 43, Issue:20
Discovery of (R)-7-cyano-2,3,4, 5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3- (phenylmethyl)-4-(2-thienylsulfonyl)-1H-1,4-benzodiazepine (BMS-214662), a farnesyltransferase inhibitor with potent preclinical antitumor activity.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID74631Inhibition of geranylgeranyl transferase2004Bioorganic & medicinal chemistry letters, Feb-09, Volume: 14, Issue:3
Synthesis of N,N'-disubstituted 3-aminobenzo[c] and [d]azepin-2-ones as potent and specific farnesyl transferase inhibitors.
AID71309Inhibition of Farnesyltransferase2004Journal of medicinal chemistry, Jan-29, Volume: 47, Issue:3
Design, synthesis, and biological activity of 4-[(4-cyano-2-arylbenzyloxy)-(3-methyl-3H-imidazol-4-yl)methyl]benzonitriles as potent and selective farnesyltransferase inhibitors.
AID1893915Inhibition of K-Ras (unknown origin) geranylgeranylation2021European journal of medicinal chemistry, Feb-05, Volume: 211Targeting KRAS mutant cancers by preventing signaling transduction in the MAPK pathway.
AID109852Percent control tumor size in mouse xenograft assay (rat H-ras transformed fibroblasts) at 100 mg/kg peroral dose2004Bioorganic & medicinal chemistry letters, Feb-09, Volume: 14, Issue:3
Synthesis of N,N'-disubstituted 3-aminobenzo[c] and [d]azepin-2-ones as potent and specific farnesyl transferase inhibitors.
AID14053Maximum concentration observed in rats at an oral dose of 50 mg/kg2000Journal of medicinal chemistry, Oct-05, Volume: 43, Issue:20
Discovery of (R)-7-cyano-2,3,4, 5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3- (phenylmethyl)-4-(2-thienylsulfonyl)-1H-1,4-benzodiazepine (BMS-214662), a farnesyltransferase inhibitor with potent preclinical antitumor activity.
AID754493Inhibition of farnesyltransferase (unknown origin) assessed as KRAS farnesylation2013Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13
Targeting mutant KRAS for anticancer therapeutics: a review of novel small molecule modulators.
AID1347414qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Secondary screen by immunofluorescence2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347412qHTS assay to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Counter screen cell viability and HiBit confirmation2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347415qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: tertiary screen by RT-qPCR2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1346248Human farnesyltransferase, CAAX box, beta (2.5.1.58 Protein farnesyltransferase)2000Journal of medicinal chemistry, Oct-05, Volume: 43, Issue:20
Discovery of (R)-7-cyano-2,3,4, 5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3- (phenylmethyl)-4-(2-thienylsulfonyl)-1H-1,4-benzodiazepine (BMS-214662), a farnesyltransferase inhibitor with potent preclinical antitumor activity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (49)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's38 (77.55)29.6817
2010's8 (16.33)24.3611
2020's3 (6.12)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 20.07

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index20.07 (24.57)
Research Supply Index4.06 (2.92)
Research Growth Index6.50 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (20.07)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials8 (16.33%)5.53%
Reviews22 (44.90%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other19 (38.78%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]